1. Home
  2. NTB vs NUVB Comparison

NTB vs NUVB Comparison

Compare NTB & NUVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Bank of N.T. Butterfield & Son Limited (The) Voting

NTB

Bank of N.T. Butterfield & Son Limited (The) Voting

HOLD

Current Price

$49.08

Market Cap

2.0B

Sector

Finance

ML Signal

HOLD

NUVB

Nuvation Bio Inc.

HOLD

Current Price

$8.55

Market Cap

2.4B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NTB
NUVB
Founded
1858
2018
Country
Bermuda
United States
Employees
1306
N/A
Industry
Commercial Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.0B
2.4B
IPO Year
2016
N/A

Fundamental Metrics

Financial Performance
Metric
NTB
NUVB
Price
$49.08
$8.55
Analyst Decision
Hold
Strong Buy
Analyst Count
3
8
Target Price
$50.67
$9.63
AVG Volume (30 Days)
148.4K
10.2M
Earning Date
10-28-2025
11-03-2025
Dividend Yield
4.08%
N/A
EPS Growth
17.07
N/A
EPS
5.27
N/A
Revenue
$599,452,000.00
$26,748,000.00
Revenue This Year
$4.46
$283.17
Revenue Next Year
N/A
$340.98
P/E Ratio
$9.32
N/A
Revenue Growth
4.60
1137.19
52 Week Low
$34.77
$1.54
52 Week High
$49.22
$8.70

Technical Indicators

Market Signals
Indicator
NTB
NUVB
Relative Strength Index (RSI) 75.85 76.08
Support Level $44.36 $7.46
Resistance Level $46.76 $8.24
Average True Range (ATR) 0.81 0.62
MACD 0.24 0.13
Stochastic Oscillator 95.99 97.20

Price Performance

Historical Comparison
NTB
NUVB

About NTB Bank of N.T. Butterfield & Son Limited (The) Voting

Bank of N.T Butterfield & Son Ltd is a full-service bank and wealth manager. It operates the business through three geographic segments, Bermuda, Cayman Islands, the Channel Islands and the UK. The company offers banking services, comprised of retail and corporate banking, and wealth management, which consists of trust, private banking, and asset management. The company generates a majority of its revenue from Bermuda, and the Cayman Islands segments.

About NUVB Nuvation Bio Inc.

Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor specifically designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes differentiated, novel oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in their different stages of development. The company generates revenue through out-licensing collaborative agreements with its customers located in China and Japan.

Share on Social Networks: